

MATRIX Technology Accelerator Domain 1—Seed Project RFA  
RFA2022-054  
Fact-finding question

The MATRIX team would like to remind applicants of the scope of the request for application (RFA). Successful applications will propose a scope of work to develop an innovative concept in the form of a product, drug-delivery system, drug, laboratory technique, or diagnostic tool. Furthermore, applications with strong collaboration, mentoring, and/or capacity strengthening in MATRIX Sub-Saharan African countries (Kenya, South Africa, and Zimbabwe) will be prioritized. [Refer to the RFA](#) for additional information or reach out to the PATH team at [MatrixTechAcceleratorRFA@path.org](mailto:MatrixTechAcceleratorRFA@path.org).

Question from applicant:

1. Dolutegravir (DTG) is a key component of the fixed-dose combination antiretroviral therapy TLD (tenofovir/lamivudine/dolutegravir (TDF/3TC/DTG). TLD is listed on the WHO essential medicines list and is widely used in developing countries. DTG in combination with lamivudine (trade name: Dovato) is effective in HIV treatment and prevention of transmission. Recent studies of long-acting DTG prodrug formulation showed its potential in both treatment and PrEP settings (Nature Comm. 2022(13) 3226).

Will the MATRIX team consider proposals that work on DTG, given its future potential for use in PrEP settings?

**Yes, DTG is an appropriate compound to work with under this funding mechanism.**